Neil R. Poulter
Imperial College London
Publications 470
Type 2 diabetes increases the risk of cardiovascular and renal complications, but early risk prediction can lead to timely intervention and better outcomes. Through summary statistics of meta-analyses of published genome-wide association studies performed in over 1.2 million of individuals, we combined 9 PRS gathering genomic variants associated to cardiovascular and renal diseases and their key risk factors into one logistic regression model, to predict micro- and macrovascular endpoints of dia...
#1Cees J. Tack (Radboud University Nijmegen)H-Index: 37
#2S Jacob (Praxis)H-Index: 2
Last.Julio Rosenstock (Lunenfeld-Tanenbaum Research Institute)H-Index: 113
view all 13 authors...
#1Cheryl CarcelH-Index: 7
#2Bruce NealH-Index: 82
Last.John ChalmersH-Index: 85
view all 10 authors...
Objective:We evaluated the characteristics of patients with treatment-resistant hypertension (TRH) and the prevalence of TRH in a large multicountry sample of specialist tertiary centres.Methods:The Survey of PatIents with treatment ResIstant hyperTension (SPIRIT) study was a retrospective review of
1 CitationsSource
#1Aslam Amod (UKZN: University of KwaZulu-Natal)H-Index: 5
#2John B. Buse (UNC: University of North Carolina at Chapel Hill)H-Index: 97
Last.Neil R. Poulter (Imperial College London)H-Index: 70
view all 11 authors...
Introduction The associations of chronic kidney disease (CKD) severity, cardiovascular disease (CVD), and insulin with the risks of major adverse cardiovascular events (MACE), mortality, and severe hypoglycemia in patients with type 2 diabetes (T2D) at high cardiovascular (CV) risk are not known. This secondary, pooled analysis of data from the DEVOTE trial examined whether baseline glomerular filtration rate (GFR) categories were associated with a higher risk of these outcomes.
#1Gijs F.N. Berkelmans (UU: Utrecht University)H-Index: 3
Last.Jannick A.N. Dorresteijn (UU: Utrecht University)H-Index: 4
view all 18 authors...
Although group-level effectiveness of lipid, blood pressure, glucose, and aspirin treatment for prevention of cardiovascular disease (CVD) has been proven by trials, important differences in absolute effectiveness exist between individuals. We aim to develop and validate a prediction tool for individualizing lifelong CVD prevention in people with Type 2 diabetes mellitus (T2DM) predicting life-years gained without myocardial infarction or stroke. We developed and validated the Diabetes Lifetime-...
9 CitationsSource
#1James E. SharmanH-Index: 32
#2Eoin O'Brien FrcpH-Index: 74
Last.George S. StergiouH-Index: 50
view all 36 authors...
#1Anshika Sharma (Public Health Foundation of India)H-Index: 1
#2Arun P. Jose (Public Health Foundation of India)H-Index: 2
Last.Ambuj Roy (AIIMS: All India Institute of Medical Sciences)H-Index: 26
view all 13 authors...
1 CitationsSource